Back to results

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

Primary Purpose

Brain and Central Nervous System Tumors

Status

Withdrawn

Phase

Not Applicable

Locations

Study Type

Interventional

Intervention

laboratory biomarker analysis

biopsy

magnetic resonance imaging

gadopentetate dimeglumine

About this trial

This is an interventional diagnostic trial for Brain and Central Nervous System Tumors focused on measuring adult brain stem glioma, adult ependymoma, adult craniopharyngioma, adult medulloblastoma, adult meningioma, adult glioblastoma, adult oligodendroglioma, adult anaplastic astrocytoma, adult myxopapillary ependymoma, adult anaplastic ependymoma, adult anaplastic oligodendroglioma, adult mixed glioma, adult pineal parenchymal tumor, adult central nervous system germ cell tumor, adult pilocytic astrocytoma, adult subependymoma, adult diffuse astrocytoma, adult ependymoblastoma, adult pineocytoma, adult pineoblastoma, adult meningeal hemangiopericytoma, adult choroid plexus tumor, adult grade III meningioma, adult giant cell glioblastoma, adult gliosarcoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Newly diagnosed surgically resectable brain tumor PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Able to tolerate gadopentetate dimeglumine contrast Medically stable PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics

Sites / Locations

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

NCT ID

NCT00005790

First Posted

June 2, 2000

Last Updated

June 8, 2012

Sponsor

Northwestern University

Collaborators

National Cancer Institute (NCI)

1. Study Identification

Unique Protocol Identification Number

NCT00005790

Brief Title

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

Official Title

Perfusion Magnetic Resonance Imaging of Brain Tumors: Correlation With Indicators of Angiogenesis

Study Type

Interventional

2. Study Status

Record Verification Date

June 2012

Overall Recruitment Status

Withdrawn

Why Stopped

Unable to accrue subjects.

Study Start Date

April 1996 (undefined)

Primary Completion Date

May 1999 (undefined)

Study Completion Date

May 1999 (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Northwestern University

Collaborators

National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary

RATIONALE: Perfusion magnetic resonance imaging may be an effective method of measuring the growth of blood vessels in brain tumors. These measurements may help doctors better diagnose and treat brain tumors. PURPOSE: Pilot study to determine the effectiveness of perfusion magnetic resonance imaging in measuring the growth of blood vessels in newly diagnosed brain tumors.

Detailed Description

OBJECTIVES: I. Correlate the findings of perfusion magnetic resonance imaging with known tissue and serum markers of angiogenesis in patients with newly diagnosed surgically resectable brain tumors. OUTLINE: Patients undergo perfusion magnetic resonance imaging (MRI) scanning with contrast in conjunction with preoperative conventional MRI scanning with contrast. Patients receive gadopentetate dimeglumine IV over 5 seconds prior to perfusion MRI. Gadopentetate dimeglumine is administered at a slower rate prior to conventional MRI. Patients undergo blood draw to determine urokinase type plasminogen activator levels. After completion of perfusion and conventional MRI scanning, brain tumor tissue samples are obtained during surgical resection to determine tumor grade and type and urokinase type plasminogen activator and basic fibroblast growth factor levels. If CSF removal is required during surgery, then CSF samples are collected to determine urokinase type plasminogen activator and basic fibroblast growth factor levels. PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Brain and Central Nervous System Tumors

Keywords

adult brain stem glioma, adult ependymoma, adult craniopharyngioma, adult medulloblastoma, adult meningioma, adult glioblastoma, adult oligodendroglioma, adult anaplastic astrocytoma, adult myxopapillary ependymoma, adult anaplastic ependymoma, adult anaplastic oligodendroglioma, adult mixed glioma, adult pineal parenchymal tumor, adult central nervous system germ cell tumor, adult pilocytic astrocytoma, adult subependymoma, adult diffuse astrocytoma, adult ependymoblastoma, adult pineocytoma, adult pineoblastoma, adult meningeal hemangiopericytoma, adult choroid plexus tumor, adult grade III meningioma, adult giant cell glioblastoma, adult gliosarcoma

7. Study Design

Primary Purpose

Diagnostic

Study Phase

Not Applicable

Enrollment

0 (Actual)

8. Arms, Groups, and Interventions

Intervention Type

Other

Intervention Name(s)

laboratory biomarker analysis

Intervention Type

Procedure

Intervention Name(s)

biopsy

Intervention Type

Procedure

Intervention Name(s)

magnetic resonance imaging

Intervention Type

Radiation

Intervention Name(s)

gadopentetate dimeglumine

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Hunt H. Batjer, MD

Organizational Affiliation

Robert H. Lurie Cancer Center

Official's Role

Study Chair

12. IPD Sharing Statement

Learn more about this trial

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

We'll reach out to this number within 24 hrs